A multi-institutional phase ii study of su101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. - Ko,Y.J.; Small,E.J.; Kabbinavar,F.; Chachoua,A.; Taneja,S.; Reese,D.; DePaoli,A.; Hannah,A.; Balk,S.P.; Bubley,G.J. (Clin Cancer Res, 2001)